(NIH.gov)
2 Dec. 2018. While much the world watched, and disapproved of, a Chinese researcher editing the genomes of embryos leading to the birth of twins, Editas Medicine in Cambridge, Massachusetts received the go-ahead to conduct a clinical trial using the genome editing technique Crispr. On Friday, the Food and Drug Administration, in an approved investigational new drug application, authorized Editas to test Crispr as a treatment for a rare inherited eye disease known as Leber congenital amaurosis type 10.
Here’s what else we reported on last week:
- Infographic – HIV Infections Growing in Eastern Europe
- Project to Catalog Precision Lung Cancer Immunotherapies
- Nanotech Polymers Deliver More Effective Arthritis Therapy
- Prosthetic Joint Provides More Natural Wrist Movements
- Personalized Computer Models Developed for Heart Disease
- Vital Signs Electronic Tag Designed to Aid First Responders
- Company Formed to Advance Sickle Cell Gene Therapy
- FDA Approves Biomarker-Targeting Cancer Drug
- 3-D Printed Scaffolds with Stem Cells, Sensors Studied to Repair Bones
- U.K. Pharmas, Regulators Agree on Faster Drug Review
* * *
RSS - Posts
You must be logged in to post a comment.